Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients

Table 4

Pioglitazone group parameters of patients at the beginning and at the end of the study.

Parameters	Beginning ()	End ()	P
FBG (mmol/L)	7.64 ± 1.99	7.14 ± 1.62	0.23
SBP (mmHg)	137.88 ± 16.89	137.44 ± 19.38	0.92
HbA1c (%)	6.94 ± 0.91	6.45 ± 0.70	0.04
BMI (kg/m^2)	25.94 ± 1.45	26.99 ± 1.87	0.01
TC (mmol/L)	4.61 ± 0.91	4.55 ± 0.79	0.75
TG (mmol/L)	1.88 ± 1.44	1.90 ± 1.44	0.95
NHDL (mmol/L)	3.68 ± 0.92	3.40 ± 1.32	0.37
HDL (mmol/L)	1.01 ± 0.24	1.16 ± 0.23	0.02
LDL (mmol/L)	2.69 ± 0.96	2.52 ± 0.76	0.42
UA (μmol/L)	371.28 ± 73.87	370.76 ± 75.33	0.98
IMT (mm)	1.20 ± 0.14	1.16 ± 0.12	0.26
Cr (μmol/L)	84.48 ± 15.06	82.43 ± 13.49	0.53
IL-6 (pg/mL)	14.32 ± 3.97	12.27 ± 3.91	0.03
ADPN (ng/mL)	11.77 ± 3.36	14.06 ± 4.44	0.01